IDEAS home Printed from https://ideas.repec.org/f/pst545.html
   My authors  Follow this author

Tom Stargardt

Personal Details

First Name:Tom
Middle Name:
Last Name:Stargardt
Suffix:
RePEc Short-ID:pst545
http://www.wiso.uni-hamburg.de/en/professuren/hcm/team/stargardt-tom/

Affiliation

Hamburg Center for Health Economics (HCHE)
Universität Hamburg

Hamburg, Germany
http://www.hche.de/

:


RePEc:edi:chhamde (more details at EDIRC)

Research output

as
Jump to: Working papers Articles

Working papers

  1. Stargardt, Tom & Schreyögg, Jonas & Kondofersky, Ivan, 2012. "Measuring the relationship between costs and outcomes: The example of Acute Myocardial Infarction in German hospitals," hche Research Papers 2012/04, University of Hamburg, Hamburg Center for Health Economics (hche).
  2. Busse, Reinhard & Stargardt, Tom & Schreyögg, Jonas & Simon, Claudia & Martin, Maria, 2005. "Defining benefit catalogues and entitlements to health care in Germany: Decision makers, decision criteria and taxonomy of catalogues," Discussion Papers 2005/5, Technische Universität Berlin, School of Economics and Management.
  3. Farhauer, Oliver & Borchardt, Katja & Stargardt, Tom, 2004. "Bürgerversicherung: Die Wirkung von Kopfprämien auf den Arbeitsmarkt," Discussion Papers 2004/8, Technische Universität Berlin, School of Economics and Management.
  4. Kathrin Roll & Tom Stargardt & Jonas Schreyögg, "undated". "Effect of Type of Insurance and Income on Waiting Time for Outpatient Care," Working Papers 2011/03, Hamburg Center for Health Economics, University of Hamburg.

Articles

  1. Carl Rudolf Blankart & Tom Stargardt, 2017. "Preferred supplier contracts in post-patent prescription drug markets," Health Care Management Science, Springer, vol. 20(3), pages 419-432, September.
  2. Dmitrij Achelrod & Jonas Schreyögg & Tom Stargardt, 2017. "Health-economic evaluation of home telemonitoring for COPD in Germany: evidence from a large population-based cohort," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(7), pages 869-882, September.
  3. Simon Frey & Carl R. Blankart & Tom Stargardt, 2016. "Economic Burden and Quality-of-Life Effects of Chronic Lymphocytic Leukemia: A Systematic Review of the Literature," PharmacoEconomics, Springer, vol. 34(5), pages 479-498, May.
  4. Florian Hofer & Dmitrij Achelrod & Tom Stargardt, 2016. "Cost-Utility Analysis of Telemonitoring Interventions for Patients with Chronic Obstructive Pulmonary Disease (COPD) in Germany," Applied Health Economics and Health Policy, Springer, vol. 14(6), pages 691-701, December.
  5. Guhl, Dennis & Stargardt, Tom & Schneider, Udo & Fischer, Katharina E., 2016. "Dispensing behaviour of pharmacies in prescription drug markets," Health Policy, Elsevier, vol. 120(2), pages 190-197.
  6. Achelrod, Dmitrij & Welte, Tobias & Schreyögg, Jonas & Stargardt, Tom, 2016. "Costs and outcomes of the German disease management programme (DMP) for chronic obstructive pulmonary disease (COPD)—A large population-based cohort study," Health Policy, Elsevier, vol. 120(9), pages 1029-1039.
  7. Fischer, Katharina Elisabeth & Heisser, Thomas & Stargardt, Tom, 2016. "Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia," Health Policy, Elsevier, vol. 120(10), pages 1115-1122.
  8. Katharina Elisabeth Fischer & Tom Stargardt, 2016. "The diffusion of generics after patent expiry in Germany," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(8), pages 1027-1040, November.
  9. Dmitrij Achelrod & Tom Stargardt, 2014. "Cost-Utility Analysis Comparing Heavy-Weight and Light-Weight Mesh in Laparoscopic Surgery for Unilateral Inguinal Hernias," Applied Health Economics and Health Policy, Springer, vol. 12(2), pages 151-163, April.
  10. Tom Stargardt & Jonas Schreyögg & Ivan Kondofersky, 2014. "Measuring The Relationship Between Costs And Outcomes: The Example Of Acute Myocardial Infarction In German Hospitals," Health Economics, John Wiley & Sons, Ltd., vol. 23(6), pages 653-669, June.
  11. Simon Frey & Roland Linder & Georg Juckel & Tom Stargardt, 2014. "Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(2), pages 133-142, March.
  12. Laura Haas & Tom Stargardt & Jonas Schreyoegg & Rico Schlösser & Burghard Klapp & Gerhard Danzer, 2013. "The Trade-off Between Costs and Quality of Care in the Treatment of Psychosomatic Patients with Somatoform Pain Disorder," Applied Health Economics and Health Policy, Springer, vol. 11(4), pages 359-368, August.
  13. Vandoros, Sotiris & Stargardt, Tom, 2013. "Reforms in the Greek pharmaceutical market during the financial crisis," Health Policy, Elsevier, vol. 109(1), pages 1-6.
  14. Michael Bäumler & Tom Stargardt & Jonas Schreyögg & Reinhard Busse, 2012. "Cost Effectiveness of Drug-Eluting Stents in Acute Myocardial Infarction Patients in Germany," Applied Health Economics and Health Policy, Springer, vol. 10(4), pages 235-248, July.
  15. Stargardt, Tom & Schreyögg, Jonas, 2012. "A framework to evaluate the effects of small area variations in healthcare infrastructure on diagnostics and patient outcomes of rare diseases based on administrative data," Health Policy, Elsevier, vol. 105(2), pages 110-118.
  16. Laura Haas & Tom Stargardt & Jonas Schreyoegg, 2012. "Cost-effectiveness of open versus laparoscopic appendectomy: a multilevel approach with propensity score matching," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(5), pages 549-560, October.
  17. Kathrin Roll & Tom Stargardt & Jonas Schreyögg, 2012. "Effect of Type of Insurance and Income on Waiting Time for Outpatient Care," The Geneva Papers on Risk and Insurance - Issues and Practice, Palgrave Macmillan;The Geneva Association, vol. 37(4), pages 609-632, October.
  18. Tom Stargardt, 2011. "Modelling pharmaceutical price changes in Germany: a function of competition and regulation," Applied Economics, Taylor & Francis Journals, vol. 43(29), pages 4515-4526.
  19. Michael Drummond & Bengt Jönsson & Frans Rutten & Tom Stargardt, 2011. "Reimbursement of pharmaceuticals: reference pricing versus health technology assessment," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 12(3), pages 263-271, June.
  20. Carl Blankart & Tom Stargardt & Jonas Schreyögg, 2011. "Availability of and Access to Orphan Drugs," PharmacoEconomics, Springer, vol. 29(1), pages 63-82, January.
  21. Jonas Schreyögg & Tom Stargardt & Oliver Tiemann, 2011. "Costs and quality of hospitals in different health care systems: a multi‐level approach with propensity score matching," Health Economics, John Wiley & Sons, Ltd., vol. 20(1), pages 85-100, January.
  22. Tom Stargardt, 2010. "The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in Germany," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(3), pages 267-277, June.
  23. Jonas Schreyögg & Oliver Tiemann & Tom Stargardt & Reinhard Busse, 2008. "Cross-country comparisons of costs: the use of episode-specific transitive purchasing power parities with standardised cost categories," Health Economics, John Wiley & Sons, Ltd., vol. 17(S1), pages 95-103.
  24. Tom Stargardt, 2008. "Health service costs in Europe: cost and reimbursement of primary hip replacement in nine countries," Health Economics, John Wiley & Sons, Ltd., vol. 17(S1), pages 9-20.
  25. Stargardt, Tom & Schreyögg, Jonas & Busse, Reinhard, 2007. "Pricing behaviour of pharmacies after market deregulation for OTC drugs: The case of Germany," Health Policy, Elsevier, vol. 84(1), pages 30-38, November.
  26. Jonas Schreyögg & Tom Stargardt & Oliver Tiemann & Reinhard Busse, 2006. "Methods to determine reimbursement rates for diagnosis related groups (DRG): A comparison of nine European countries," Health Care Management Science, Springer, vol. 9(3), pages 215-223, August.
  27. J. Schreyögg & T. Stargardt & M. Velasco-Garrido & R. Busse, 2005. "Defining the “Health Benefit Basket” in nine European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(1), pages 2-10, November.
  28. Reinhard Busse & Tom Stargardt & Jonas Schreyögg, 2005. "Determining the “Health Benefit Basket” of the Statutory Health Insurance scheme in Germany," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(1), pages 30-36, November.

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Working papers

  1. Stargardt, Tom & Schreyögg, Jonas & Kondofersky, Ivan, 2012. "Measuring the relationship between costs and outcomes: The example of Acute Myocardial Infarction in German hospitals," hche Research Papers 2012/04, University of Hamburg, Hamburg Center for Health Economics (hche).

    Cited by:

    1. Laura Haas & Tom Stargardt & Jonas Schreyoegg & Rico Schlösser & Burghard Klapp & Gerhard Danzer, 2013. "The Trade-off Between Costs and Quality of Care in the Treatment of Psychosomatic Patients with Somatoform Pain Disorder," Applied Health Economics and Health Policy, Springer, vol. 11(4), pages 359-368, August.
    2. Mareike Heimeshoff & Jonas Schreyögg & Lukas Kwietniewski, 2014. "Cost and technical efficiency of physician practices: a stochastic frontier approach using panel data," Health Care Management Science, Springer, vol. 17(2), pages 150-161, June.
    3. Milstein, Ricarda & Schreyoegg, Jonas, 2016. "Pay for performance in the inpatient sector: A review of 34 P4P programs in 14 OECD countries," Health Policy, Elsevier, vol. 120(10), pages 1125-1140.
    4. Lindlbauer, Ivonne & Schreyögg, Jonas & Winter, Vera, 2016. "Changes in technical efficiency after quality management certification: A DEA approach using difference-in-difference estimation with genetic matching in the hospital industry," European Journal of Operational Research, Elsevier, vol. 250(3), pages 1026-1036.

  2. Busse, Reinhard & Stargardt, Tom & Schreyögg, Jonas & Simon, Claudia & Martin, Maria, 2005. "Defining benefit catalogues and entitlements to health care in Germany: Decision makers, decision criteria and taxonomy of catalogues," Discussion Papers 2005/5, Technische Universität Berlin, School of Economics and Management.

    Cited by:

    1. Reinhard Busse & Tom Stargardt & Jonas Schreyögg, 2005. "Determining the “Health Benefit Basket” of the Statutory Health Insurance scheme in Germany," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(1), pages 30-36, November.

  3. Farhauer, Oliver & Borchardt, Katja & Stargardt, Tom, 2004. "Bürgerversicherung: Die Wirkung von Kopfprämien auf den Arbeitsmarkt," Discussion Papers 2004/8, Technische Universität Berlin, School of Economics and Management.

    Cited by:

    1. Feil, Michael & Klinger, Sabine & Zika, Gerd, 2006. "Sozialabgaben und Beschäftigung : Simulationen mit drei makroökonomischen Modellen," IAB Discussion Paper 200622, Institut für Arbeitsmarkt- und Berufsforschung (IAB), Nürnberg [Institute for Employment Research, Nuremberg, Germany].
    2. Kallweit Manuel & Kohlmeier Anabell, 2014. "Zusatzbeiträge in der Gesetzlichen Krankenversicherung / Income-independent Surcharges in German Statutory Health Insurance: Weiterentwicklungsoptionen und ihre finanziellen sowie allokativen Effekte ," Journal of Economics and Statistics (Jahrbuecher fuer Nationaloekonomie und Statistik), De Gruyter, vol. 234(4), pages 490-517, August.

  4. Kathrin Roll & Tom Stargardt & Jonas Schreyögg, "undated". "Effect of Type of Insurance and Income on Waiting Time for Outpatient Care," Working Papers 2011/03, Hamburg Center for Health Economics, University of Hamburg.

    Cited by:

    1. Christian Bührer & Steffen Fetzer & Christian Hagist, 2017. "Cui bono? - Die Bürgerversicherung und die Beihilfe," WHU Working Paper Series - Economics Group 17-05, WHU - Otto Beisheim School of Management.
    2. Schmitz, Hendrik, 2013. "Practice budgets and the patient mix of physicians – The effect of a remuneration system reform on health care utilisation," Journal of Health Economics, Elsevier, vol. 32(6), pages 1240-1249.
    3. Roll, Kathrin & Stargardt, Tom & Schreyögg, Jonas, 2011. "Effect of type of insurance and income on waiting time for outpatient care," hche Research Papers 2011/03, University of Hamburg, Hamburg Center for Health Economics (hche).
    4. Blankart, Carl Rudolf, 2012. "Does healthcare infrastructure have an impact on delay in diagnosis and survival?," Health Policy, Elsevier, vol. 105(2), pages 128-137.
    5. Christian Bührer & Steffen Fetzer & Christian Hagist, 2017. "Das Hamburger Beihilfemodell - Ein Vergleich der internen Renditen von GKV und PKV," WHU Working Paper Series - Economics Group 17-06, WHU - Otto Beisheim School of Management.
    6. Emmert, Martin & Meier, Florian & Heider, Ann-Kathrin & Dürr, Christoph & Sander, Uwe, 2014. "What do patients say about their physicians? An analysis of 3000 narrative comments posted on a German physician rating website," Health Policy, Elsevier, vol. 118(1), pages 66-73.
    7. Kifmann, Mathias, 2017. "Competition policy for health care provision in Germany," Health Policy, Elsevier, vol. 121(2), pages 119-125.
    8. Heinrich, Nils & Wübker, Ansgar & Wuckel, Christiane, 2017. "Waiting times for outpatient treatment in Germany: New experimental evidence from primary data," Ruhr Economic Papers 683, RWI - Leibniz-Institut für Wirtschaftsforschung, Ruhr-University Bochum, TU Dortmund University, University of Duisburg-Essen.
    9. Lindsey Woodworth, 2014. "The doctor will be with you ... shortly?," Journal of Regulatory Economics, Springer, vol. 45(2), pages 138-174, April.
    10. Diana Weidlich & Fredrik L. Andersson & Matthias Oelke & Marcus John Drake & Aino Fianu Jonasson & Julian F. Guest, 2017. "Annual direct and indirect costs attributable to nocturia in Germany, Sweden, and the UK," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(6), pages 761-771, July.

Articles

  1. Carl Rudolf Blankart & Tom Stargardt, 2017. "Preferred supplier contracts in post-patent prescription drug markets," Health Care Management Science, Springer, vol. 20(3), pages 419-432, September.

    Cited by:

    1. Herr, Annika & Suppliet, Moritz, 2012. "Pharmaceutical prices under regulation: Tiered co-payments and reference pricing in Germany," DICE Discussion Papers 48, University of Düsseldorf, Düsseldorf Institute for Competition Economics (DICE).

  2. Dmitrij Achelrod & Jonas Schreyögg & Tom Stargardt, 2017. "Health-economic evaluation of home telemonitoring for COPD in Germany: evidence from a large population-based cohort," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(7), pages 869-882, September.

    Cited by:

    1. Klaus Kaier & Silvia Hils & Stefan Fetzer & Philip Hehn & Anja Schmid & Dieter Hauschke & Lioudmila Bogatyreva & Bernd Jänigen & Przemyslaw Pisarski, 2017. "Results of a randomized controlled trial analyzing telemedically supported case management in the first year after living donor kidney transplantation - a budget impact analysis from the healthcare pe," Health Economics Review, Springer, vol. 7(1), pages 1-8, December.

  3. Simon Frey & Carl R. Blankart & Tom Stargardt, 2016. "Economic Burden and Quality-of-Life Effects of Chronic Lymphocytic Leukemia: A Systematic Review of the Literature," PharmacoEconomics, Springer, vol. 34(5), pages 479-498, May.

    Cited by:

    1. James Buchanan & Sarah Wordsworth & Ruth Clifford & Pauline Robbe & Jenny C. Taylor & Anna Schuh & Samantha J. L. Knight, 2017. "Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic Leukaemia: A Cost-Effectiveness Analysis," PharmacoEconomics, Springer, vol. 35(8), pages 845-858, August.

  4. Achelrod, Dmitrij & Welte, Tobias & Schreyögg, Jonas & Stargardt, Tom, 2016. "Costs and outcomes of the German disease management programme (DMP) for chronic obstructive pulmonary disease (COPD)—A large population-based cohort study," Health Policy, Elsevier, vol. 120(9), pages 1029-1039.

    Cited by:

    1. Kifmann, Mathias, 2017. "Competition policy for health care provision in Germany," Health Policy, Elsevier, vol. 121(2), pages 119-125.
    2. Dmitrij Achelrod & Jonas Schreyögg & Tom Stargardt, 2017. "Health-economic evaluation of home telemonitoring for COPD in Germany: evidence from a large population-based cohort," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(7), pages 869-882, September.

  5. Tom Stargardt & Jonas Schreyögg & Ivan Kondofersky, 2014. "Measuring The Relationship Between Costs And Outcomes: The Example Of Acute Myocardial Infarction In German Hospitals," Health Economics, John Wiley & Sons, Ltd., vol. 23(6), pages 653-669, June.
    See citations under working paper version above.
  6. Simon Frey & Roland Linder & Georg Juckel & Tom Stargardt, 2014. "Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(2), pages 133-142, March.

    Cited by:

    1. Mark Pennington & Paul McCrone, 2017. "The Cost of Relapse in Schizophrenia," PharmacoEconomics, Springer, vol. 35(9), pages 921-936, September.
    2. Jan Zeidler & Jörg Mahlich & Wolfgang Greiner & Stephan Heres, 2013. "Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany," Applied Health Economics and Health Policy, Springer, vol. 11(5), pages 509-521, October.

  7. Laura Haas & Tom Stargardt & Jonas Schreyoegg & Rico Schlösser & Burghard Klapp & Gerhard Danzer, 2013. "The Trade-off Between Costs and Quality of Care in the Treatment of Psychosomatic Patients with Somatoform Pain Disorder," Applied Health Economics and Health Policy, Springer, vol. 11(4), pages 359-368, August.

    Cited by:

    1. Valerie Moran & Rowena Jacobs, 2018. "Investigating the relationship between costs and outcomes for English mental health providers: a bi-variate multi-level regression analysis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(5), pages 709-718, June.

  8. Vandoros, Sotiris & Stargardt, Tom, 2013. "Reforms in the Greek pharmaceutical market during the financial crisis," Health Policy, Elsevier, vol. 109(1), pages 1-6.

    Cited by:

    1. Vogler, Sabine & Zimmermann, Nina & de Joncheere, Kees, 2016. "Policy interventions related to medicines: Survey of measures taken in European countries during 2010–2015," Health Policy, Elsevier, vol. 120(12), pages 1363-1377.
    2. Balasopoulos, T. & Charonis, A. & Athanasakis, K. & Kyriopoulos, J. & Pavi, E., 2017. "Why do generic drugs fail to achieve an adequate market share in Greece? Empirical findings and policy suggestions," Health Policy, Elsevier, vol. 121(3), pages 265-272.
    3. Ifanti, Amalia A. & Argyriou, Andreas A. & Kalofonou, Foteini H. & Kalofonos, Haralabos P., 2013. "Financial crisis and austerity measures in Greece: Their impact on health promotion policies and public health care," Health Policy, Elsevier, vol. 113(1), pages 8-12.
    4. José A. Tapia Granados & Javier M. Rodriguez, 2015. "Health, Economic Crisis, and Austerity: A Comparison of Greece, Finland, and Iceland," Mathematica Policy Research Reports 1cdbac6dc6c548e3877b7b180, Mathematica Policy Research.
    5. Simou, Effie & Koutsogeorgou, Eleni, 2014. "Effects of the economic crisis on health and healthcare in Greece in the literature from 2009 to 2013: A systematic review," Health Policy, Elsevier, vol. 115(2), pages 111-119.
    6. George Fragkiadakis & Michael Doumpos & Constantin Zopounidis & Christophe Germain, 2016. "Operational and economic efficiency analysis of public hospitals in Greece," Post-Print hal-01414677, HAL.
    7. George Fragkiadakis & Michael Doumpos & Constantin Zopounidis & Christophe Germain, 2016. "Operational and economic efficiency analysis of public hospitals in Greece," Annals of Operations Research, Springer, vol. 247(2), pages 787-806, December.
    8. Mastorakis, Kostis & Siskos, Eleftherios, 2016. "Value focused pharmaceutical strategy determination with multicriteria decision analysis techniques," Omega, Elsevier, vol. 59(PA), pages 84-96.
    9. Petrou, Panagiotis & Vandoros, Sotiris, 2015. "Cyprus in crisis: Recent changes in the pharmaceutical market and options for further reforms without sacrificing access to or quality of treatment," Health Policy, Elsevier, vol. 119(5), pages 563-568.
    10. Casagranda, Ivo & Costantino, Giorgio & Falavigna, Greta & Furlan, Raffaello & Ippoliti, Roberto, 2016. "Artificial Neural Networks and risk stratification models in Emergency Departments: The policy maker's perspective," Health Policy, Elsevier, vol. 120(1), pages 111-119.
    11. Cavalieri, Marina & Guccio, Calogero & Rizzo, Ilde, 2017. "On the role of environmental corruption in healthcare infrastructures: An empirical assessment for Italy using DEA with truncated regression approach," Health Policy, Elsevier, vol. 121(5), pages 515-524.
    12. Jaume Puig-Junoy & Santiago Rodríguez-Feijoó & Beatriz Lopez-Valcarcel, 2014. "Paying for Formerly Free Medicines in Spain After 1 Year of Co-Payment: Changes in the Number of Dispensed Prescriptions," Applied Health Economics and Health Policy, Springer, vol. 12(3), pages 279-287, June.
    13. Goranitis, Ilias & Siskou, Olga & Liaropoulos, Lycourgos, 2014. "Health policy making under information constraints: An evaluation of the policy responses to the economic crisis in Greece," Health Policy, Elsevier, vol. 117(3), pages 279-284.
    14. Quaglio, GianLuca & Karapiperis, Theodoros & Van Woensel, Lieve & Arnold, Elleke & McDaid, David, 2013. "Austerity and health in Europe," Health Policy, Elsevier, vol. 113(1), pages 13-19.

  9. Stargardt, Tom & Schreyögg, Jonas, 2012. "A framework to evaluate the effects of small area variations in healthcare infrastructure on diagnostics and patient outcomes of rare diseases based on administrative data," Health Policy, Elsevier, vol. 105(2), pages 110-118.

    Cited by:

    1. Peter Eibich & Nicolas R. Ziebarth, 2013. "Analyzing Regional Variation in Health Care Utilization Using (Rich) Household Microdata," SOEPpapers on Multidisciplinary Panel Data Research 551, DIW Berlin, The German Socio-Economic Panel (SOEP).
    2. Blankart, Carl Rudolf, 2012. "Does healthcare infrastructure have an impact on delay in diagnosis and survival?," Health Policy, Elsevier, vol. 105(2), pages 128-137.

  10. Kathrin Roll & Tom Stargardt & Jonas Schreyögg, 2012. "Effect of Type of Insurance and Income on Waiting Time for Outpatient Care," The Geneva Papers on Risk and Insurance - Issues and Practice, Palgrave Macmillan;The Geneva Association, vol. 37(4), pages 609-632, October.
    See citations under working paper version above.
  11. Tom Stargardt, 2011. "Modelling pharmaceutical price changes in Germany: a function of competition and regulation," Applied Economics, Taylor & Francis Journals, vol. 43(29), pages 4515-4526.

    Cited by:

    1. Herr, Annika & Suppliet, Moritz, 2012. "Pharmaceutical prices under regulation: Tiered co-payments and reference pricing in Germany," DICE Discussion Papers 48, University of Düsseldorf, Düsseldorf Institute for Competition Economics (DICE).
    2. Hostenkamp, Gisela, 2013. "Do follow-on therapeutic substitutes induce price competition between hospital medicines? Evidence from the Danish hospital sector," Health Policy, Elsevier, vol. 111(1), pages 68-77.
    3. Izabela Jelovac, 2015. "On the relationship between the negotiated prices of pharmaceuticals and the patients' co-payment," Economics Bulletin, AccessEcon, vol. 35(1), pages 481-493.
    4. Petrou, Panagiotis & Vandoros, Sotiris, 2015. "Cyprus in crisis: Recent changes in the pharmaceutical market and options for further reforms without sacrificing access to or quality of treatment," Health Policy, Elsevier, vol. 119(5), pages 563-568.
    5. Michael Mueller & Alexander Frenzel, 2015. "Competitive pricing within pharmaceutical classes: evidence on “follow-on” drugs in Germany 1993–2008," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(1), pages 73-82, January.
    6. Vandoros, Sotiris & Stargardt, Tom, 2013. "Reforms in the Greek pharmaceutical market during the financial crisis," Health Policy, Elsevier, vol. 109(1), pages 1-6.

  12. Michael Drummond & Bengt Jönsson & Frans Rutten & Tom Stargardt, 2011. "Reimbursement of pharmaceuticals: reference pricing versus health technology assessment," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 12(3), pages 263-271, June.

    Cited by:

    1. Vogler, Sabine & Zimmermann, Nina & de Joncheere, Kees, 2016. "Policy interventions related to medicines: Survey of measures taken in European countries during 2010–2015," Health Policy, Elsevier, vol. 120(12), pages 1363-1377.
    2. Afschin Gandjour, 2013. "Reference Pricing and Price Negotiations for Innovative New Drugs," PharmacoEconomics, Springer, vol. 31(1), pages 11-14, January.
    3. Sabine Vogler & Valérie Paris & Alessandra Ferrario & Veronika J. Wirtz & Kees Joncheere & Peter Schneider & Hanne Bak Pedersen & Guillaume Dedet & Zaheer-Ud-Din Babar, 2017. "How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries," Applied Health Economics and Health Policy, Springer, vol. 15(3), pages 307-321, June.
    4. Daems, Rutger & Maes, Edith & Ramani, Shyama V., 2011. "Global Framework for Differential Pricing of Pharmaceuticals," MERIT Working Papers 054, United Nations University - Maastricht Economic and Social Research Institute on Innovation and Technology (MERIT).
    5. Hanna Koskinen & Elina Ahola & Leena Saastamoinen & Hennamari Mikkola & Jaana Martikainen, 2014. "The impact of reference pricing and extension of generic substitution on the daily cost of antipsychotic medication in Finland," Health Economics Review, Springer, vol. 4(1), pages 1-10, December.
    6. Bengt Jönsson, 2011. "Relative effectiveness and the European pharmaceutical market," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 12(2), pages 97-102, April.
    7. Petrou, Panagiotis & Vandoros, Sotiris, 2015. "Cyprus in crisis: Recent changes in the pharmaceutical market and options for further reforms without sacrificing access to or quality of treatment," Health Policy, Elsevier, vol. 119(5), pages 563-568.
    8. Aris Angelis & Ansgar Lange & Panos Kanavos, 2018. "Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(1), pages 123-152, January.
    9. Livio Garattini & Katelijne Vooren, 2013. "Could co-payments on drugs help to make EU health care systems less open to political influence?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(5), pages 709-713, October.
    10. Michael Drummond & Adrian Towse, 2012. "Is it time to reconsider the role of patient co-payments for pharmaceuticals in Europe?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(1), pages 1-5, February.

  13. Jonas Schreyögg & Tom Stargardt & Oliver Tiemann, 2011. "Costs and quality of hospitals in different health care systems: a multi‐level approach with propensity score matching," Health Economics, John Wiley & Sons, Ltd., vol. 20(1), pages 85-100, January.

    Cited by:

    1. Stefan Voigt, 2016. "Determinants of judicial efficiency: a survey," European Journal of Law and Economics, Springer, vol. 42(2), pages 183-208, October.
    2. Tiemann, Oliver & Schreyögg, Jonas, 2011. "Changes in hospital efficiency after privatization," hche Research Papers 2011/02, University of Hamburg, Hamburg Center for Health Economics (hche).
    3. Tom Stargardt & Jonas Schreyögg & Ivan Kondofersky, 2014. "Measuring The Relationship Between Costs And Outcomes: The Example Of Acute Myocardial Infarction In German Hospitals," Health Economics, John Wiley & Sons, Ltd., vol. 23(6), pages 653-669, June.
    4. Häkkinen, Unto & Iversen, Tor & Peltola, Mikko & Seppälä, Timo T. & Malmivaara, Antti & Belicza, Éva & Fattore, Giovanni & Numerato, Dino & Heijink, Richard & Medin, Emma & Rehnberg, Clas, 2013. "Health care performance comparison using a disease-based approach: The EuroHOPE project," Health Policy, Elsevier, vol. 112(1), pages 100-109.
    5. Stargardt, Tom & Schreyögg, Jonas, 2012. "A framework to evaluate the effects of small area variations in healthcare infrastructure on diagnostics and patient outcomes of rare diseases based on administrative data," Health Policy, Elsevier, vol. 105(2), pages 110-118.
    6. Helmut Herwartz & Christoph Strumann, 2012. "On the effect of prospective payment on local hospital competition in Germany," Health Care Management Science, Springer, vol. 15(1), pages 48-62, March.
    7. Laura Haas & Tom Stargardt & Jonas Schreyoegg, 2012. "Cost-effectiveness of open versus laparoscopic appendectomy: a multilevel approach with propensity score matching," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(5), pages 549-560, October.

  14. Tom Stargardt, 2010. "The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in Germany," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(3), pages 267-277, June.

    Cited by:

    1. Herr, Annika & Suppliet, Moritz, 2012. "Pharmaceutical prices under regulation: Tiered co-payments and reference pricing in Germany," DICE Discussion Papers 48, University of Düsseldorf, Düsseldorf Institute for Competition Economics (DICE).
    2. Thengilsdottir, G. & Gardarsdottir, H. & Almarsdottir, A.B. & McClure, C.B. & Heerdink, E.R., 2013. "The association between lifting an administrative restriction on antidepressant dispensing and treatment patterns in Iceland," Health Policy, Elsevier, vol. 111(2), pages 193-199.
    3. Nika Marđetko & Mitja Kos, 2018. "Introduction of therapeutic reference pricing in Slovenia and its economic consequences," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(4), pages 571-584, May.
    4. Patricia M. Danzon & Michael F. Furukawa, 2011. "Cross-National Evidence on Generic Pharmaceuticals: Pharmacy vs. Physician-Driven Markets," NBER Working Papers 17226, National Bureau of Economic Research, Inc.
    5. Katharina Elisabeth Fischer & Tom Stargardt, 2016. "The diffusion of generics after patent expiry in Germany," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(8), pages 1027-1040, November.
    6. Simone Ghislandi & Patrizio Armeni & Claudio Jommi, 2013. "The impact of generic reference pricing in Italy, a decade on," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(6), pages 959-969, December.
    7. Matteo Galizzi & Simone Ghislandi & Marisa Miraldo, 2011. "Effects of Reference Pricing in Pharmaceutical Markets," PharmacoEconomics, Springer, vol. 29(1), pages 17-33, January.
    8. Livio Garattini & Katelijne Vooren, 2013. "Could co-payments on drugs help to make EU health care systems less open to political influence?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(5), pages 709-713, October.

  15. Jonas Schreyögg & Oliver Tiemann & Tom Stargardt & Reinhard Busse, 2008. "Cross-country comparisons of costs: the use of episode-specific transitive purchasing power parities with standardised cost categories," Health Economics, John Wiley & Sons, Ltd., vol. 17(S1), pages 95-103.

    Cited by:

    1. Martine M. Bellanger & Zeynep Or, 2008. "What can we learn from a cross-country comparison of the costs of child delivery?," Health Economics, John Wiley & Sons, Ltd., vol. 17(S1), pages 47-57.
    2. Mahlich, Jörg & Sindern, Jörn & Suppliet, Moritz, 2014. "Vergleichbarkeit internationaler Arzneimittelpreise: Internationale Preisreferenzierung in Deutschland durch das AMNOG," DICE Ordnungspolitische Perspektiven 60, University of Düsseldorf, Düsseldorf Institute for Competition Economics (DICE).
    3. Martine Bellanger & Céline Pichery & Dominique Aerts & Marika Berglund & Argelia Castaño & Mája Čejchanová & Pierre Crettaz & Fred Davidson & Marta Esteban & Marc E Fischer & Anca Elena Gurzau & Katar, 2013. "Economic benefits of methylmercury exposure control in Europe: Monetary value of neurotoxicity prevention," Post-Print hal-01505639, HAL.
    4. David Epstein & Anne Mason & Andrea Manca, 2008. "The hospital costs of care for stroke in nine European countries," Health Economics, John Wiley & Sons, Ltd., vol. 17(S1), pages 21-31.
    5. Reinhard Busse & Jonas Schreyögg & Peter C. Smith, 2008. "Variability in healthcare treatment costs amongst nine EU countries - results from the Health BASKET project," Health Economics, John Wiley & Sons, Ltd., vol. 17(S1), pages 1-8.
    6. Mads D. Faurby & Olaf C. Jensen & Lulu Hjarnoe & Despena Andrioti, 2017. "The costs of repatriating an ill seafarer: a micro-costing approach," Health Economics Review, Springer, vol. 7(1), pages 1-8, December.
    7. Rice, N & Robone, S & Smith, P.C, 2008. "International Comparison of Public Sector Performance: The Use of Anchoring Vignettes to adjust Self-Reported Data," Health, Econometrics and Data Group (HEDG) Working Papers 08/28, HEDG, c/o Department of Economics, University of York.

  16. Tom Stargardt, 2008. "Health service costs in Europe: cost and reimbursement of primary hip replacement in nine countries," Health Economics, John Wiley & Sons, Ltd., vol. 17(S1), pages 9-20.

    Cited by:

    1. Laudicella, M. & Siciliani, L. & Cookson, R., 2010. "Waiting Times and Socioeconomic Status: Evidence from England," Health, Econometrics and Data Group (HEDG) Working Papers 10/05, HEDG, c/o Department of Economics, University of York.
    2. Majo, M.C., 2010. "A microeconometric analysis of health care utilization in Europe," Other publications TiSEM 1cf5fd2f-8146-4ef8-8eb5-e, Tilburg University, School of Economics and Management.
    3. Wohlschlegel, Ansgar & Feess, Eberhard & Mueller, Helge, 2017. "Reimbursement Schemes for Hospitals: The Impact of Case and Firm Characteristics," Annual Conference 2016 (Augsburg): Demographic Change 145776, Verein für Socialpolitik / German Economic Association.
    4. Majo, Maria Cristina & van Soest, Arthur, 2012. "Income and health care utilization among the 50+ in Europe and the US," Applied Econometrics, Publishing House "SINERGIA PRESS", vol. 28(4), pages 3-22.
    5. Melberg, Hans Olav, 2011. "Some problems with international comparisons of health spending – and a suggestion about how to quantify the size of the problems," HERO On line Working Paper Series 2011:4, Oslo University, Health Economics Research Programme.
    6. Jonas Schreyögg & Oliver Tiemann & Tom Stargardt & Reinhard Busse, 2008. "Cross-country comparisons of costs: the use of episode-specific transitive purchasing power parities with standardised cost categories," Health Economics, John Wiley & Sons, Ltd., vol. 17(S1), pages 95-103.
    7. Reinhard Busse & Jonas Schreyögg & Peter C. Smith, 2008. "Variability in healthcare treatment costs amongst nine EU countries - results from the Health BASKET project," Health Economics, John Wiley & Sons, Ltd., vol. 17(S1), pages 1-8.
    8. Glinos, Irene A. & Baeten, Rita & Maarse, Hans, 2010. "Purchasing health services abroad: Practices of cross-border contracting and patient mobility in six European countries," Health Policy, Elsevier, vol. 95(2-3), pages 103-112, May.

  17. Stargardt, Tom & Schreyögg, Jonas & Busse, Reinhard, 2007. "Pricing behaviour of pharmacies after market deregulation for OTC drugs: The case of Germany," Health Policy, Elsevier, vol. 84(1), pages 30-38, November.

    Cited by:

    1. Vogler, Sabine & Habimana, Katharina & Arts, Danielle, 2014. "Does deregulation in community pharmacy impact accessibility of medicines, quality of pharmacy services and costs? Evidence from nine European countries," Health Policy, Elsevier, vol. 117(3), pages 311-327.

  18. Jonas Schreyögg & Tom Stargardt & Oliver Tiemann & Reinhard Busse, 2006. "Methods to determine reimbursement rates for diagnosis related groups (DRG): A comparison of nine European countries," Health Care Management Science, Springer, vol. 9(3), pages 215-223, August.

    Cited by:

    1. Heimeshoff, Mareike & Schreyögg, Jonas, 2013. "Estimation of a physician practice cost function," hche Research Papers 2013/07, University of Hamburg, Hamburg Center for Health Economics (hche).
    2. Gartner, Daniel & Kolisch, Rainer, 2014. "Scheduling the hospital-wide flow of elective patients," European Journal of Operational Research, Elsevier, vol. 233(3), pages 689-699.
    3. Vitikainen, Kirsi & Street, Andrew & Linna, Miika, 2009. "Estimation of hospital efficiency--Do different definitions and casemix measures for hospital output affect the results?," Health Policy, Elsevier, vol. 89(2), pages 149-159, February.
    4. Longo, R & Miraldo, M & Street, A, 2009. "Price regulation of pluralistic markets subject to provider collusion," Working Papers 1454, Imperial College, London, Imperial College Business School.
    5. Hamada, Hironori & Sekimoto, Miho & Imanaka, Yuichi, 2012. "Effects of the per diem prospective payment system with DRG-like grouping system (DPC/PDPS) on resource usage and healthcare quality in Japan," Health Policy, Elsevier, vol. 107(2), pages 194-201.
    6. Dirk Schürmann & Sonja Sorensen & Erwin Cock & Sandeep Duttagupta & Ansgar Resch, 2009. "Cost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in Germany," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 10(1), pages 65-79, February.
    7. Giovanni Iuzzolino, 2008. "Demand and supply of hospital services. International trends," Questioni di Economia e Finanza (Occasional Papers) 27, Bank of Italy, Economic Research and International Relations Area.
    8. Matthias Vogl, 2012. "Assessing DRG cost accounting with respect to resource allocation and tariff calculation: the case of Germany," Health Economics Review, Springer, vol. 2(1), pages 1-12, December.
    9. Oliver Tiemann, 2008. "Variations in hospitalisation costs for acute myocardial infarction - a comparison across Europe," Health Economics, John Wiley & Sons, Ltd., vol. 17(S1), pages 33-45.
    10. Jonas Schreyögg, 2008. "A micro-costing approach to estimating hospital costs for appendectomy in a Cross-European context," Health Economics, John Wiley & Sons, Ltd., vol. 17(S1), pages 59-69.
    11. Michael Bäumler & Tom Stargardt & Jonas Schreyögg & Reinhard Busse, 2012. "Cost Effectiveness of Drug-Eluting Stents in Acute Myocardial Infarction Patients in Germany," Applied Health Economics and Health Policy, Springer, vol. 10(4), pages 235-248, July.
    12. Siok Tan & Leona Hakkaart-van Roijen & B. Ineveld & W. Redekop, 2013. "Explaining length of stay variation of episodes of care in the Netherlands," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(6), pages 919-927, December.
    13. Giovanni Fattore & Aleksandra Torbica, 2008. "Cost and reimbursement of cataract surgery in Europe: a cross-country comparison," Health Economics, John Wiley & Sons, Ltd., vol. 17(S1), pages 71-82.
    14. Jérôme LARTIGAU, 2013. "Prospective Payment Systems And Evolution Of Management Control In French Hospitals: An Overview," Scientific Bulletin - Economic Sciences, University of Pitesti, vol. 12(2), pages 24-39.
    15. Schreyögg, Jonas & Bäumler, Michael & Busse, Reinhard, 2009. "Balancing adoption and affordability of medical devices in Europe," Health Policy, Elsevier, vol. 92(2-3), pages 218-224, October.
    16. Roll, Kathrin & Stargardt, Tom & Schreyögg, Jonas, 2011. "Effect of type of insurance and income on waiting time for outpatient care," hche Research Papers 2011/03, University of Hamburg, Hamburg Center for Health Economics (hche).
    17. Vomhof, Markus, 2016. "Hospital competition with heterogeneous patient groups: Incentives and regulation," Ruhr Economic Papers 624, RWI - Leibniz-Institut für Wirtschaftsforschung, Ruhr-University Bochum, TU Dortmund University, University of Duisburg-Essen.
    18. Tom Stargardt, 2008. "Health service costs in Europe: cost and reimbursement of primary hip replacement in nine countries," Health Economics, John Wiley & Sons, Ltd., vol. 17(S1), pages 9-20.
    19. Vogl, Matthias, 2013. "Improving patient-level costing in the English and the German ‘DRG’ system," Health Policy, Elsevier, vol. 109(3), pages 290-300.
    20. Andrew Street & Kirsi Vitikainen & Afsaneh Bjorvatn & Anne Hvenegaard, 2007. "Introducing activity-based financing: a review of experience in Australia, Denmark, Norway and Sweden," Working Papers 030cherp, Centre for Health Economics, University of York.
    21. Vogl, Matthias, 2014. "Hospital financing: Calculating inpatient capital costs in Germany with a comparative view on operating costs and the English costing scheme," Health Policy, Elsevier, vol. 115(2), pages 141-151.
    22. Miraldo, M & Crea, G & Longo, R & Street, A, 2014. "Collusion in regulated pluralistic markets," Working Papers 15402, Imperial College, London, Imperial College Business School.
    23. Jonas Schreyögg & Oliver Tiemann & Tom Stargardt & Reinhard Busse, 2008. "Cross-country comparisons of costs: the use of episode-specific transitive purchasing power parities with standardised cost categories," Health Economics, John Wiley & Sons, Ltd., vol. 17(S1), pages 95-103.
    24. Machiel Westerdijk & Joost Zuurbier & Martijn Ludwig & Sarah Prins, 2012. "Defining care products to finance health care in the Netherlands," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(2), pages 203-221, April.
    25. Raulinajtys-Grzybek, Monika, 2014. "Cost accounting models used for price-setting of health services: An international review," Health Policy, Elsevier, vol. 118(3), pages 341-353.
    26. Stefan Felder, 2009. "The variance of length of stay and the optimal DRG outlier payments," International Journal of Health Economics and Management, Springer, vol. 9(3), pages 279-289, September.
    27. Sutherland, Jason Murray & Walker, Jan, 2008. "Challenges of rehabilitation case mix measurement in Ontario hospitals," Health Policy, Elsevier, vol. 85(3), pages 336-348, March.
    28. Bisceglia, Michele & Cellini, Roberto & Grilli, Luca, 2017. "Regional regulators in healthcare service under quality competition: A game theoretical model," MPRA Paper 80507, University Library of Munich, Germany.
    29. Baxter, Pamela E. & Hewko, Sarah J. & Pfaff, Kathryn A. & Cleghorn, Laura & Cunningham, Barbara J. & Elston, Dawn & Cummings, Greta G., 2015. "Leaders’ experiences and perceptions implementing activity-based funding and pay-for-performance hospital funding models: A systematic review," Health Policy, Elsevier, vol. 119(8), pages 1096-1110.

  19. J. Schreyögg & T. Stargardt & M. Velasco-Garrido & R. Busse, 2005. "Defining the “Health Benefit Basket” in nine European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(1), pages 2-10, November.

    Cited by:

    1. E. Wetering & E. Stolk & N. Exel & W. Brouwer, 2013. "Balancing equity and efficiency in the Dutch basic benefits package using the principle of proportional shortfall," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(1), pages 107-115, February.
    2. S. Tan & F. Rutten & B. Ineveld & W. Redekop & L. Hakkaart-van Roijen, 2009. "Comparing methodologies for the cost estimation of hospital services," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 10(1), pages 39-45, February.
    3. Ongaro, Edoardo & Ferré, Francesca & Fattore, Giovanni, 2015. "The fiscal crisis in the health sector: Patterns of cutback management across Europe," Health Policy, Elsevier, vol. 119(7), pages 954-963.
    4. Samantha Smith, 2010. "The Irish ‘health basket’: a basket case?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(3), pages 343-350, June.
    5. Fischer, Katharina E. & Rogowski, Wolf H. & Leidl, Reiner & Stollenwerk, Björn, 2013. "Transparency vs. closed-door policy: Do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis," Health Policy, Elsevier, vol. 112(3), pages 187-196.
    6. Jonas Schreyögg & Oliver Tiemann & Tom Stargardt & Reinhard Busse, 2008. "Cross-country comparisons of costs: the use of episode-specific transitive purchasing power parities with standardised cost categories," Health Economics, John Wiley & Sons, Ltd., vol. 17(S1), pages 95-103.
    7. Smith, Peter C. & Anell, Anders & Busse, Reinhard & Crivelli, Luca & Healy, Judith & Lindahl, Anne Karin & Westert, Gert & Kene, Tobechukwu, 2012. "Leadership and governance in seven developed health systems," Health Policy, Elsevier, vol. 106(1), pages 37-49.
    8. Katharina Fischer & Reiner Leidl, 2014. "Analysing coverage decision-making: opening Pandora’s box?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(9), pages 899-906, December.
    9. Jonas Schreyögg & Tom Stargardt & Oliver Tiemann & Reinhard Busse, 2006. "Methods to determine reimbursement rates for diagnosis related groups (DRG): A comparison of nine European countries," Health Care Management Science, Springer, vol. 9(3), pages 215-223, August.
    10. Kleinhout-Vliek, Tineke & de Bont, Antoinette & Boer, Bert, 2017. "The bare necessities? A realist review of necessity argumentations used in health care coverage decisions," Health Policy, Elsevier, vol. 121(7), pages 731-744.

  20. Reinhard Busse & Tom Stargardt & Jonas Schreyögg, 2005. "Determining the “Health Benefit Basket” of the Statutory Health Insurance scheme in Germany," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(1), pages 30-36, November.

    Cited by:

    1. Henschke, Cornelia, 2012. "Provision and financing of assistive technology devices in Germany: A bureaucratic odyssey? The case of amyotrophic lateral sclerosis and Duchenne muscular dystrophy," Health Policy, Elsevier, vol. 105(2), pages 176-184.
    2. Fourie, Carina & Biller-Andorno, Nikola & Wild, Verina, 2014. "Systematically evaluating the impact of diagnosis-related groups (DRGs) on health care delivery: A matrix of ethical implications," Health Policy, Elsevier, vol. 115(2), pages 157-164.
    3. Olberg, Britta & Perleth, Matthias & Busse, Reinhard, 2014. "The new regulation to investigate potentially beneficial diagnostic and therapeutic methods in Germany: Up to international standard?," Health Policy, Elsevier, vol. 117(2), pages 135-145.
    4. Florian Hofer & Dmitrij Achelrod & Tom Stargardt, 2016. "Cost-Utility Analysis of Telemonitoring Interventions for Patients with Chronic Obstructive Pulmonary Disease (COPD) in Germany," Applied Health Economics and Health Policy, Springer, vol. 14(6), pages 691-701, December.
    5. J. Schreyögg & T. Stargardt & M. Velasco-Garrido & R. Busse, 2005. "Defining the “Health Benefit Basket” in nine European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(1), pages 2-10, November.
    6. Stargardt, Tom & Schreyögg, Jonas & Busse, Reinhard, 2007. "Pricing behaviour of pharmacies after market deregulation for OTC drugs: The case of Germany," Health Policy, Elsevier, vol. 84(1), pages 30-38, November.
    7. Haeder, Simon F., 2014. "Balancing adequacy and affordability?: Essential Health Benefits under the Affordable Care Act," Health Policy, Elsevier, vol. 118(3), pages 285-291.

More information

Research fields, statistics, top rankings, if available.

Statistics

Access and download statistics for all items

Co-authorship network on CollEc

NEP Fields

NEP is an announcement service for new working papers, with a weekly report in each of many fields. This author has had 1 paper announced in NEP. These are the fields, ordered by number of announcements, along with their dates. If the author is listed in the directory of specialists for this field, a link is also provided.
  1. No paper was announced in a field specific NEP report

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, Tom Stargardt should log into the RePEc Author Service.

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.

IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.